PT Pyridam Farma Tbk (ISX:PYFA) Operating Income: Rp-114,857 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:PYFA PT Pyridam Farma Tbk ISX:PYFA
65 GF Score
Price Rp236.00
GF Value Rp230.48
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is PT Pyridam Farma Tbk Operating Income?

PT Pyridam Farma Tbk ISX:PYFA +10.28% 65 Operating Income is Rp-114,857 Mil as of Jun. 2026. GuruFocus rates ISX:PYFA with a GF Score™ of 65/100 and a GF Value™ of Rp230.48 (Fairly Valued). The stock has 8 warning signs investors should review.

PT Pyridam Farma Tbk's Operating Income for the three months ended in Jun. 2026 was Rp-4,334 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was Rp-114,857 Mil.

Warning Sign:

PT Pyridam Farma Tbk had lost money in 75% of the time over the past 12quarters.

Operating Margin % is calculated as Operating Income divided by its Revenue. PT Pyridam Farma Tbk's Operating Income for the three months ended in Jun. 2026 was Rp-4,334 Mil. PT Pyridam Farma Tbk's Revenue for the three months ended in Jun. 2026 was Rp850,990 Mil. Therefore, PT Pyridam Farma Tbk's Operating Margin % for the quarter that ended in Jun. 2026 was -0.51%.

PT Pyridam Farma Tbk's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Pyridam Farma Tbk's annualized ROC % for the quarter that ended in Jun. 2026 was -0.25%. PT Pyridam Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 0.49%.


PT Pyridam Farma Tbk  (ISX:PYFA) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Pyridam Farma Tbk's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=-17335.148 * ( 1 - 0% )/( (6744665.112 + 7105763.851)/ 2 )
=-17335.148/6925214.4815
=-0.25 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7066339.232 - 575864.802 - ( 51070.682 - max(0, 1765947.864 - 1511757.182+51070.682))
=6744665.112

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7393745.535 - 566865.975 - ( 130305.523 - max(0, 1911745.08 - 1632860.789+130305.523))
=7105763.851

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Pyridam Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=15143.48/( ( (2399586.962 + max(631350.852, 0)) + (2463668.919 + max(637536.304, 0)) )/ 2 )
=15143.48/( ( 3030937.814 + 3101205.223 )/ 2 )
=15143.48/3066071.5185
=0.49 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(828625.767 + 540997.574 + 79505.193) - (575864.802 + 0 + 241912.88)
=631350.852

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(870285.53 + 546956.768 + 75834.045) - (566865.975 + 0 + 288674.064)
=637536.304

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

PT Pyridam Farma Tbk's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-4333.787/850989.791
=-0.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


PT Pyridam Farma Tbk Operating Income Related Terms


PT Pyridam Farma Tbk Operating Income Historical Data

* Premium members only.

The historical data trend for PT Pyridam Farma Tbk's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Pyridam Farma Tbk Operating Income Chart

PT Pyridam Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23,147.81 -29,982.02 -8,444.78 -29,245.37 -168,686.05

PT Pyridam Farma Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61,106.64 -22,867.99 -78,188.52 -9,467.15 -4,333.79
ISX:PYFA
65GF Score
PT Pyridam Farma Tbk ISX:PYFA
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Pyridam Farma Tbk Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-114,857 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of Rp-114,857 Mil mean?
PT Pyridam Farma Tbk (ISX:PYFA) has a Operating Income of Rp-114,857 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on PT Pyridam Farma Tbk and its competitors.
Is PT Pyridam Farma Tbk's Operating Income too high?
PT Pyridam Farma Tbk's current Operating Income is Rp-114,857 Mil. Overall, PT Pyridam Farma Tbk has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Operating Income compare to ZTS and UTHR?
PT Pyridam Farma Tbk's Operating Income of Rp-114,857 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on PT Pyridam Farma Tbk and its competitors. PT Pyridam Farma Tbk's current Operating Income is Rp-114,857 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Fairly Valued. The stock's GF Value™ is Rp230.48, compared to a current price of Rp236.00 — trading 2.4% above its estimated fair value. The current Operating Income is Rp-114,857 Mil. PT Pyridam Farma Tbk's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Operating Income is Rp-114,857 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be overvalued. The current stock price of Rp236.00 is trading 2.4% above its estimated GF Value™ of Rp230.48. GuruFocus considers PT Pyridam Farma Tbk to be Fairly Valued.

Key valuation signals for ISX:PYFA:

  • Operating Income: Rp-114,857 Mil
  • GF Value™: Rp230.48 vs. price of Rp236.00 (2.4% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Pyridam Farma Tbk Business Description

Address Jl. Jenderal Sudirman Kav. 21, Sinar Mas Land Plaza Sudirman 12th Floor, RT 10/RW 01 Kuningan, Karet, Jakarta Selatan, Jakarta, IDN, 12920
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
65GF Score

Get the complete analysis for ISX:PYFA

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp236.00
Price
Rp230.48
GF Value